Hancock Whitney Corp Sells 2,235 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hancock Whitney Corp trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,916 shares of the medical equipment provider’s stock after selling 2,235 shares during the period. Hancock Whitney Corp’s holdings in Lantheus were worth $1,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of LNTH. Principal Securities Inc. purchased a new position in shares of Lantheus in the fourth quarter valued at $28,000. Janney Montgomery Scott LLC boosted its stake in Lantheus by 6.2% during the fourth quarter. Janney Montgomery Scott LLC now owns 8,005 shares of the medical equipment provider’s stock valued at $497,000 after buying an additional 467 shares during the period. Norges Bank purchased a new position in shares of Lantheus during the fourth quarter worth about $29,956,000. PNC Financial Services Group Inc. grew its stake in Lantheus by 14.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider’s stock worth $596,000 after buying an additional 1,202 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Lantheus during the 4th quarter worth $1,977,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. B. Riley lifted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Finally, Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Buying and Selling

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Up 1.4 %

Shares of Lantheus stock opened at $110.05 on Monday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company has a 50-day moving average of $105.51 and a 200 day moving average of $84.39. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s revenue was up 22.5% compared to the same quarter last year. During the same period last year, the firm posted $1.40 earnings per share. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.